Low-dose fractionated radiotherapy and concomitant chemotherapy for recurrent or progressive glioblastoma: Final report of a pilot study

Strahlentherapie und Onkologie

Volumn 190, Issue 4, 2014, Pages 370-376

  Balducci, M ^a   Diletto, B ^a   Chiesa, S ^a   D'Agostino, G R ^a   Gambacorta, M A ^a   Ferro, M ^a   Colosimo, C ^a   Maira, G ^a   Anile, C ^a   Valentini, V ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Glioblastoma multiforme; Low dose radiotherapy; Neoplasm recurrence, local; Palliative care; Progressive

Indexed keywords

CISPLATIN; FOTEMUSTINE; TEMOZOLOMIDE;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CLINICAL ARTICLE; FATIGUE; FEMALE; GLIOBLASTOMA; HEADACHE; HUMAN; LEUKOPENIA; MALE; PILOT STUDY; RADIATION DOSE; SKIN MANIFESTATION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DOSE FRACTIONATION; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; RADIOTHERAPY, CONFORMAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84897001113     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-013-0506-z     Document Type: Article

References (72)

1. Guckenberger M, Mayer M, Buttmann M et al (2011) Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme. Strahlenther Onkol 187:548-554
2. Lang O, Liebermeister E, Liesegang J, Sautter-Bihl ML (1998) Radiotherapy of glioblastoma multiforme. Feasibility of increased fraction size and shortened overall treatment. Strahlenther Onkol 174:629-632 (Pubitemid 28562089)
3. American Cancer Society (2008) Cancer facts & figures 2008. American Cancer Society, Atlanta
4. Stupp R, Mason WP, Bent MJ van den et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996 (Pubitemid 40349501)
5. Jansen EP, Dewit LG, Herk M van, Bartelink H (2000) Target volumes in radiotherapy for high-grade malignant glioma of the brain. Radiother Oncol 56:151-156 (Pubitemid 30601671)
6. Wallner KE, Galicich JH, Krol G et al (1989) Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16:1405-1409 (Pubitemid 19154322)
7. Chamberlain MC, Kormanik PA (1998) Practical guidelines for the treatment of malignant gliomas. West J Med 168:114-120 (Pubitemid 28100970)
8. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-4729 (Pubitemid 350086473)
9. Tselis N, Kolotas C, Birn G et al (2007) CT-guided interstitial HDR brachytherapy for recurrent glioblastoma multiforme. Long-term results. Strahlenther Onkol 183:563-570 (Pubitemid 47482157)
10. Henke G, Paulsen F, Steinbach JP et al (2009) Hypofractionated reirradiation for recurrent malignant glioma. Strahlenther Onkol 185:113-119
11. Fokas E, Wacker U, Gross MW (2009) Hypofractionated stereotactic reirradiation of recurrent glioblastomas: a beneficial treatment option after high-dose radiotherapy? Strahlenther Onkol 185:235-240
12. Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trial. J Clin Oncol 17:2572-2578 (Pubitemid 29368260)
13. Galanis E, Buckner JC, Maurer MJ et al (2005) Phase II trial of temsirolimus (CC1-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study. J Clin Oncol 23:5294-5304 (Pubitemid 46206983)
14. Niyazi M, Siefert A, Schwarz SB et al (2011) Therapeutic options for recurrent malignant glioma. Radiother Oncol 98:1-14
15. Perry JR, Rizek P, Cashman R et al (2008) Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach. Cancer 113:2152-2157
16. Short SC, Mitchell SA, Boulton P et al (1999) The response of human glioma cell lines to low-dose radiation exposure. Int J Radiat Biol 75:1341-1348
17. Short S, Mayes C, Woodcock M et al (1999) Low-dose hypersensitivity in the T98G human glioblastoma cell line. Int J Radiat Biol 75:847-855 (Pubitemid 29336561)
18. Beauchesne PD, Bertrand S, Branche R et al (2003) Human malignant glioma cell lines are sensitive to low radiation doses. Int J Cancer 105:33-40 (Pubitemid 36418482)
19. Krause M, Wohlfarth J, Georgi B et al (2005) Low-dose hyperradiosensitivity of human glioblastoma cell lines in vitro does not translate into improved outcome of ultrafractionated radiotherapy in vivo. Int J Radiat Biol 81:751-758 (Pubitemid 43200510)
20. Chendil D, Oakes R, Alcock RA et al (2000) Low dose fractionated radiation enhances the radiosensitization effect of paclitaxel in colorectal tumor cells with mutant p53. Cancer 89:1893-1900
21. Short SC, Kelly J, Mayes CR et al (2001) Low-dose hypersensitivity after fractionated low-dose irradiation in vitro. Int J Radiat Biol 77:655-664 (Pubitemid 32531882)
22. Dey S, Spring PM, Arnold S et al (2003) Low-dose fractionated radiation potentiates the effects of paclitaxel in wild-type and mutant p53 head and neck tumor cell lines. Clin Cancer Res 9:1557-1565 (Pubitemid 36418414)
23. Gupta S, Arnold AM, Spring P et al (2004) Low-dose fractionated radiation potentiates the effect of cisplatin independent of the hyper-radiation sensitivity phenomenon in human lung cancer cell lines [Abstract]. Proc Am Assoc Cancer Res 45
24. Arnold SM, Regine WF, Ahmed MM et al (2004) Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: results of a new treatment paradigm. Int J Radiat Oncol Biol Phys 58:1411-1417 (Pubitemid 38438301)
25. Spring PM, Arnold SM, Shajahan S et al (2004) Low dose fractionated radiation potentiates the effects of taxotere in nude mice xenografts of squamous cell carcinoma of head and neck. Cell Cycle 3:479-485 (Pubitemid 40278242)
26. Regine WF, Hanna N, Garofalo MC et al (2007) Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm. Int J Radiat Oncol Biol Phys 68:172-177 (Pubitemid 46589824)
27. Simpson L, Galanis E (2006) Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates. Expert Rev Anticancer Ther 6:1593-1607 (Pubitemid 44883962)
28. Brandes AA, Tosoni A, Basso U et al (2004) Secondline chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 22:4779-4786
29. Franceschi E, Omuro AM, Lassman AB et al (2005) Salvage temozolomide for prior temozolomide responders. Cancer 104:2473-2476 (Pubitemid 41691570)
30. Meulemans A, Giroux B, Hannoun P et al (1991) Comparative diffusion study of two nitrosoureas: carmustine and fotemustine in normal rat brain, human and rat brain biopsies. Chemotherapy 37:86-92
31. Fischel JL, Formento P, Etienne MC, Gioanni J et al (1990) In vitro chemosensitivity testing of fotemustine (S 10036), a new antitumor nitrosourea. Cancer Chemother Pharmacol 25:337-341 (Pubitemid 20048640)
32. Fabrini MG, Silvano G, Lolli I et al (2009) A multi-institutional phase II study on second-line fotemustine chemotherapy in recurrent glioblastoma. J Neurooncol 92:79-86
33. Scoccianti S, Detti B, Sardaro A et al (2008) Secondline chemotherapy with fotemustine in temozolomide- pretreated patients with relapsing glioblastoma: a single institution experience. Anticancer Drugs 19:613-620
34. De Wit MC, Bruin HG de, Eijkenboom W et al (2004) Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63:535-537 (Pubitemid 39031388)
35. Emami B, Lyman j, Brown A et al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109-122
36. Lawrence YR, Li XA, Naqa I el et al (2010) Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys 76(3 Suppl):S20-S27
37. Balducci M, D'Agostino GR, Manfrida S et al (2010) Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: long-term analysis of a phase II study. J Neurooncol 97:95-100
38. De Bonis P, Anile C, Pompucci A et al (2012) Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma. Acta Neurochir (Wien) 154:1371-1378
39. Rodier JM, Da Costa L, Adams D et al (1996) Fotemustine and cisplatin association in patients with recurrent malignant glioma. Proc Am Sol Clin
40. Lambin P, Malaise EP, Joiner MC (1994) The effect of very low radiation doses on the human bludder cell line RT112. Radiother Oncol 32:63-72 (Pubitemid 24246765)
41. Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC) v4.0. ctep.cancer.gov/reporting/ctc.html. Accessed 29. Dec 2013
42. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280 (Pubitemid 20195640)
43. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2008 (Revised March 23, 2012). http://www.cbtrus.org/reports/reports.html. Accessed 29. Dec 2013
44. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466
45. Taghian A, Ramsay J, Allalunis-Turner J et al (1993) Intrinsic radiation sensitivity may not be the major determinant of the poor clinical outcome of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 25:243-249 (Pubitemid 23048776)
46. Johannessen TC, Bjerkvig R, Tysnes BB (2008) DNA repair and cancer stem-like cells - potential partners in glioma drug resistance? Cancer Treat Rev 34:558-567
47. Lowe SW, Ruley HE, Jacks T, Housman DE et al (1993) P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967 (Pubitemid 23289454)
48. Benjamin B, David C, Dieter L et al (2010) Defective p53 antiangiogenic signaling in glioblastoma. Neuro Oncol 12:894-907
49. Nieder C, Adam M, Molls M, Grosu AL (2006) Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit Rev Oncol Hematol 60:181-193 (Pubitemid 44709618)
50. Franceschi E, Tosoni A, Bartolini S et al (2009) Treatment options for recurrent glioblastoma: pitfalls and future trends. Expert Rev Anticancer Ther 9:613-619
51. Lin SH, Kleinberg LR (2008) Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. Expert Rev Anticancer Ther 8:343-359 (Pubitemid 351836283)
52. Attenello FJ, Mukherjee D, Datoo G et al (2008) Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 15:2887-2893
53. Hart MG, Grant R, Garside R et al (2008) Chemotherapeutic wafers for high grade glioma. Cochrane Database Syst Rev 3:CD007294
54. Gilbert MR (2011) Recurrent glioblastoma: a fresh look at current therapies and emerging novel approaches. Semin Oncol 38(Suppl 4):S21-S33
55. Marples B, Wouters BG, Collis SJ et al (2004) Low-dose hyper-radiosensitivity: a consequence of ineffective cell cycle arrest of radiationdamaged G2-phase cells. Radiat Res 161:247-255 (Pubitemid 40797066)
56. Enns L, Bogen KT, Wizniak J et al (2004) Low- dose radiation hypersensitivity is associated with p53-dependent apoptosis. Mol Cancer Res 2:557-566 (Pubitemid 39403384)
57. Brandes AA, Tosoni A, Cavallo G et al (2006) Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 95:1155-1160 (Pubitemid 44658477)
58. Brada M, Hoang-Xuan K, Rampling R et al (2001) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12:259-266 (Pubitemid 32223879)
59. Yung WK, Albright RE, Olson J et al (2000) A phase II study of temozolomide vs. procarbazine in patients with Glioblastoma multiforme at first relapse. Br J Cancer 83:588-593 (Pubitemid 30636298)
60. Wick W, Steinbach JP, Kuker WM et al (2004) One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 62:2113-2115 (Pubitemid 38738235)
61. Wick A, Felsberg J, Steinbach JP et al (2007) Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25:3357-3361 (Pubitemid 47325623)
62. Joiner MC, Denekamp J, Maughan RL (1986) The use of 'top-up' experiments to investigate the effect of very small doses per fraction in mouse skin. Int J Radiat Biol Relat Stud Phys Chem Med 49:565-580 (Pubitemid 16105455)
63. Joiner MC, Johns H (1988) Renal damage in the mouse: the response to very small doses per fraction. Radiat Res 114:385-398
64. Turesson I, Nyman J, Qvarnström F et al (2010) A low-dose hypersensitive keratinocyte loss in response to fractionated radiotherapy is associated with growth arrest and apoptosis. Radiother Oncol 94:90-101
65. Rachidi W, Harfourche G, Lemaitre G et al (2007) Sensing radiosensitivity of human epidermal stem cells. Radiother Oncol 83:267-276 (Pubitemid 46915550)
66. Gay H (2010) Role of the linear-quadratic model in high doses per fraction. Radiother Oncol 94:122-123
67. Courdi A (2010) High doses per fraction and the linear-quadratic model. Radiother Oncol 94:121-122
68. Short SC, Woodcock M, Marples B, Joiner MC et al (2003) Effects of cell cycle phase on low-dose hyper- radiosensitivity. Int J Radiat Biol 79:99-105 (Pubitemid 36183068)
69. Beauchesne P, Bernier V, Carnin C et al (2010) Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapy. Neuro Oncol 12:595-602
70. Valentini V, Massaccesi M, Balducci M et al (2010) Low-dose hyperradiosensitivity: is there a place for future investigation in clinical settings? Int J Radiat Oncol Biol Phys 76:535-539
71. Mantini G, Valentini V, Meduri B et al (2102) Low-dose radiotherapy as a chemo-potentiator of a chemotherapy regimen with pemetrexed for recurrent non-small-cell lung cancer: A prospective phase II study. Radiother Oncol 105:161-166
72. Balducci M, Chiesa S, Diletto B et al (2012) Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study. Neuro Oncol 14:79-86